Operational Research Priorities to Interrupt Poliovirus Transmission in Conflict-affected and Vaccine-hesitant Settings in Pakistan
Open Forum Infectious Diseases · 13.11.2026
DOI: 10.1093/ofid/ofag744 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 13.11.2026. Verfasst von Kifayat ullah und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This Viewpoint contends that the principal obstacles to polio eradication in Pakistan are no longer technical but operational and contextual, rooted in insecurity, governance constraints, population mobility, and persistent vaccine hesitancy. We identify critical evidence gaps in implementation fidelity, community engagement, and adaptive service delivery, and propose an embedded operational research agenda integrated within immunization programs. Such an approach would generate real-time, policy-relevant evidence to guide context-sensitive strategies and sustain interruption of poliovirus transmission in conflict-affected and high-risk settings.
Zitieren
APA
ullah, K., Bukhari, M. H., Ullah, K., Shad, M. Y., Naeem, A., & Haque, U. (2026). Operational Research Priorities to Interrupt Poliovirus Transmission in Conflict-affected and Vaccine-hesitant Settings in Pakistan. Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofag744
Vancouver
ullah K, Bukhari MH, Ullah K, Shad MY, Naeem A, Haque U. Operational Research Priorities to Interrupt Poliovirus Transmission in Conflict-affected and Vaccine-hesitant Settings in Pakistan. Open Forum Infectious Diseases. 2026. doi:10.1093/ofid/ofag744
BibTeX
@article{ullah2026,
author = {ullah, Kifayat and Bukhari, Moeen Hamid and Ullah, Kalim and Shad, Muhammad Yousaf and Naeem, Amna and Haque, Ubydul},
title = {Operational Research Priorities to Interrupt Poliovirus Transmission in Conflict-affected and Vaccine-hesitant Settings in Pakistan},
journal = {Open Forum Infectious Diseases},
year = {2026},
doi = {10.1093/ofid/ofag744}
}
EUVIMED